CpG DNA, a ligand for Toll-like receptor 9 (TLR9), has been one of the most promising immunotherapeutic agents. Although there are several types of potent humanized CpG oligodeoxynucleotide (ODN), developing "all-in-one" CpG ODNs activating both B cells and plasmacytoid dendritic cells forming a stable nanoparticle without aggregation has not been successful. In this study, we generated a novel nanoparticulate K CpG ODN (K3) wrapped by the nonagonistic Dectin-1 ligand schizophyllan (SPG), K3-SPG. In sharp contrast to K3 alone, K3-SPG stimulates human peripheral blood mononuclear cells to produce a large amount of both type I and type II IFN, targeting the same endosome where IFN-inducing D CpG ODN resides without losing its K-type activity. K3-SPG thus became a potent adjuvant for induction of both humoral and cellular immune responses, particularly CTL induction, to coadministered protein antigens without conjugation. Such potent adjuvant activity of K3-SPG is attributed to its nature of being a nanoparticle rather than targeting Dectin-1 by SPG, accumulating and activating antigen-bearing macrophages and dendritic cells in the draining lymph node. K3-SPG acting as an influenza vaccine adjuvant was demonstrated in vivo in both murine and nonhuman primate models. Taken together, K3-SPG may be useful for immunotherapeutic applications that require type I and type II IFN as well as CTL induction.
CpG DNA, a ligand for Toll-like receptor 9 (TLR9), has been one of the most promising immunotherapeutic agents. Although there are several types of potent humanized CpG oligodeoxynucleotide (ODN), developing "all-in-one" CpG ODNs activating both B cells and plasmacytoid dendritic cells forming a stable nanoparticle without aggregation has not been successful. In this study, we generated a novel nanoparticulate K CpG ODN (K3) wrapped by the nonagonistic Dectin-1 ligand schizophyllan (SPG), K3-SPG. In sharp contrast to K3 alone, K3-SPG stimulates human peripheral blood mononuclear cells to produce a large amount of both type I and type II IFN, targeting the same endosome where IFN-inducing D CpG ODN resides without losing its K-type activity. K3-SPG thus became a potent adjuvant for induction of both humoral and cellular immune responses, particularly CTL induction, to coadministered protein antigens without conjugation. Such potent adjuvant activity of K3-SPG is attributed to its nature of being a nanoparticle rather than targeting Dectin-1 by SPG, accumulating and activating antigen-bearing macrophages and dendritic cells in the draining lymph node. K3-SPG acting as an influenza vaccine adjuvant was demonstrated in vivo in both murine and nonhuman primate models. Taken together, K3-SPG may be useful for immunotherapeutic applications that require type I and type II IFN as well as CTL induction.
innate immunity | two-photon microscopy | MARCO | Siglec-1 | β-glucan C pG oligodeoxynucleotide (CpG ODN) is a short (∼20 bases), single-stranded synthetic DNA fragment containing the immunostimulatory CpG motif, a potent agonist for Toll-like receptor 9 (TLR9), which activates dendritic cells (DCs) and B cells to produce type I interferons (IFNs) and inflammatory cytokines (1, 2) and acts as an adjuvant toward both Th1-type humoral and cellular immune responses, including cytotoxic T-lymphocyte (CTL) responses (3, 4) . Therefore, CpG ODN has been postulated as a possible immunotherapeutic agent against infectious diseases, cancer, asthma, and pollinosis (2, 5) .
There are at least four types of CpG ODN, each of which has a different backbone, sequence, and immunostimulatory properties (6) . D-type (also called A) CpG ODNs typically comprise one palindromic CpG motif with a phosphodiester (PO) backbone and phosphorothioate (PS) poly(G) tail, and activates plasmacytoid DCs (pDCs) to produce a large amount of IFN-α but fails to induce pDC maturation and B-cell activation (7, 8) . The three other types of ODN consist of a PS backbone. K-type (also called B) CpG ODN contains nonpalindromic multiple CpG motifs, and strongly activates B cells to produce IL-6 and pDCs to maturation but barely produces IFN-α (8, 9) . Recently, C and P CpG ODNs have been developed; these contain one and two palindromic CpG sequences, respectively, both of which can activate B cells like K-type and pDC like D-type, although C CpG ODN induces weaker IFN-α production compared with P CpG ODN (10) (11) (12) .
D and P CpG ODNs have been shown to form higher-order structures, Hoogsteen base pairing to form parallel quadruplex structures called G tetrads, and Watson-Crick base pairing between cis-and trans-palindromic portions, respectively, that are required for robust IFN-α production by pDCs (12) (13) (14) . Although such higher-order structures appear necessary for localization to early endosomes and signaling via TLR9, they suffer from product polymorphisms, aggregation, and precipitation, thereby hampering their clinical application (15) . Therefore, only K and C CpG ODNs are generally available as immunotherapeutic agents and vaccine adjuvants for human use (16, 17) . Although K CpG ODN enhances the immunogenicity of vaccines targeting infectious diseases and cancers in human clinical trials (6, 17) , chemical or physical conjugation between antigen and K CpG ODN is necessary for optimal adjuvant effects. These results indicate that these four (K, D, P, and C) types of CpG ODN have advantages and disadvantages; however, the Significance CpG oligodeoxynucleotide (ODN), a Toll-like receptor 9 ligand, is a promising immunotherapeutic agent; however, developing an IFN-inducing CpG ODN forming a stable nanoparticle without aggregation has been unsuccessful. Here we generated a nanoparticulate CpG ODN (K3) wrapped by the nonagonistic Dectin-1 ligand schizophyllan (SPG), K3-SPG. K3-SPG stimulates human peripheral blood mononuclear cells to produce large amounts of both type I and II IFN. K3-SPG thus became a potent adjuvant, especially for cytotoxic T-lymphocyte (CTL) induction to coadministered protein antigens without conjugation, which is attributable to its nanoparticulate nature rather than to targeting Dectin-1. Protective potency of K3-SPG as an influenza vaccine adjuvant was demonstrated in both murine and nonhuman primate models. K3-SPG may be used as an IFN inducer as well as a CTL inducer for immunotherapeutic applications.
Author contributions: K.K., T.A., C.C., and K.J.I. designed research; K.K., T.A., H.N., M.H., and Y.K. performed research; T.A., H.N., E.K., M.H., K.T., S.M., K.S., Y.K., Y.Y., S.S., Y.I., and S.A. contributed new reagents/analytic tools; K.K., T.A., H.N., E.K., S.K., C.C., and K.J.I. analyzed data; and K.K., T.A., E.K., and K.J.I. wrote the paper.
Conflict of interest statement: K.S. holds a patent related to schizophyllan forming a complex with nucleic acids. K.K., T.A., and K.J.I. have filed a patent application related to the content of this manuscript.
This article is a PNAS Direct Submission. development of an "all-in-one" CpG ODN activating both B cells and pDCs that forms a stable nanoparticle without aggregation has yet to be accomplished. A better strategy, targeting CpG ODN toward antigen-presenting cells (APCs), is desired to improve immunostimulatory specificity and immunotherapeutic efficacy of CpG ODNs.
Schizophyllan (SPG), a soluble β-glucan derived from Schizophyllum commune, is a drug that has been approved in Japan as an enhancer of radiotherapy in cervical carcinoma patients for the last three decades (18) . It has been shown to form a complex with polydeoxyadenylic acid (dA) as a triple-helical structure (19) . Although we previously demonstrated that mouse and humanized CpG ODN with PO poly(dA) at the 5′ end complexed with SPG enhanced cytokine production and acted as an influenza vaccine adjuvant (20, 21) , it has been difficult to achieve high yields of the CpG-SPG complex toward its more efficient and cost-effective preclinical as well as clinical development. Recently, when the PS backbone of the dA sequence was linked to CpG ODN, the efficacy of complex formation was elevated by nearly 100% (22) . However, a thorough investigation has yet to be conducted to identify the best humanized CpG sequence and optimization of factors to gain all-in-one activities of the four types of CpG ODN.
To do this, we sought to optimize a humanized CpG-SPG complex as a vaccine adjuvant and immunostimulatory agent in humans (in vitro), mice (in vitro and in vivo), and nonhuman primates (in vivo). In this study, we identified a novel K CpG ODN (K3) and SPG complex, namely K3-SPG. It forms a higherorder nanoparticle that can be completely solubilized. We found that this all-in-one K3-SPG displayed a more potent activity than, and different characteristics from, any other type of CpG ODN and previous CpG-SPG complexes.
Results
A Rod-Shaped Nano-Sized Particle of K3-SPG Gains Dual Characteristics of K-and D-Type CpG ODNs. To make a complex between CpG ODNs and schizophyllan (SPG), CpG ODNs need additional sequences of phosphorothioate backbone of 40-mer polydeoxyadenylic acid (dA 40 ) at the 5′ or 3′ end (20, 22) . Fig. 1A shows methods of CpG ODN and SPG complexation through denaturingrenaturing procedures. In this study, we selected K3 as a K-type CpG ODN. At first, we examined the immunostimulatory impacts of the 5′ and 3′ ends of CpG ODN. 5′-K3-dA 40 -3′, but not 5′-dA 40 -K3-3′, complexed with SPG-activated human peripheral blood mononuclear cells (PBMCs) to produce a robust amount of IFN-α ( Fig. 1B and Fig. S1 ). K3, K3-dA 40 , or dA 40 -K3, which are able to activate human PBMCs to produce other cytokines such as IL-6, failed to produce IFN-α ( Fig. 1B and Fig. S1 ). These results indicate that the 5′-CpG sequence (K3-SPG) is more desirable than the 3′-CpG sequence as a novel TLR9 agonist. Although some CpG ODN-induced cytokine production is known to have a dosedependent correlation, K3-SPG-induced IFN-α production is not. Given that previous reports showed that IFN-α pro-duction by K CpG ODN stimulation has a bell-shaped dose-response correlation (7), altogether these results suggest that K3-SPG still has the character of K CpG ODN.
Qualification and quantitation of K3-SPG were conducted by scanning electron microscopy (SEM) and dynamic light scattering (DLS). K3-SPG had a rod-like structure, consistent with that seen in a previous report (23) (Fig. 1C) . It appeared to be a soluble monomeric nanoparticle with an average diameter of 30 nm, comparable to SPG itself and smaller than D CpG ODN (D35) (14, 24) (Fig. 1D ). Given that K3-SPG forms a nanoparticle, we compared the immunostimulatory activities of K3-SPG with D, C, and P CpG ODNs. PBMCs stimulated with K3-SPG produced larger amounts of IFN-α and IFN-γ but at far lower concentrations than those induced by D35 (Fig. 1E ) and P and C CpG ODNs (Fig. S2 ). These results suggest that K3-SPG gains the characteristic of D CpG ODN without losing that of the K type, because these IFNs are known to be D type-specific cytokines (7, 8, 25) . To understand the dual functions of K and D CpG ODNs, we analyzed the intracellular localization of K3-SPG in bone marrow-derived macrophages (BMDMs). K3-SPG was colocalized with not only the endosomes containing K CpG ODN but also those containing D CpG ODN (Fig. 1 F and G) such as C CpG ODN (26) , suggesting that K3-SPG may transduce endosomemediated innate immune signaling pathways by K and D CpG ODNs. These results strongly suggest that K3-SPG forms a nanosized higher-order and completely solubilized particle and found that this all-in-one K3-SPG displayed a more potent activity than, and different characteristic from, any other CpG ODNs and previously known CpG-SPG complex.
K3-SPG Is a Prominent Vaccine Adjuvant That Induces Potent CTL
Responses to Protein Antigen Without Conjugation. We compared the adjuvant effects of K3, K3-dA 40 , and K3-SPG in a murine immunization model. When wild-type mice were immunized with LPS-free chicken ovalbumin protein (OVA) alone or OVA with each K3-derived adjuvant, K3-SPG induced significantly higher humoral immune responses ( Fig. 2A) and stronger T-cell responses than that induced by K3 (Fig. 2B) . Of note, tetramer assays revealed a significantly greater number of OVA-specific CD8 T cells (Fig.  2C) . We also observed very strong in vivo CTL activity against coadministered protein antigens lacking any covalent conjugation (Fig. 2D ). This strong CTL induction by K3-SPG was reproduced by peptide vaccination (Fig. 2E ) and was dose-dependent (Fig. S3) . The antigen-sparing ability of K3-SPG was so potent that comparable antibody and CD4 T-cell responses were achieved using one-hundredth the amount of OVA antigen (Fig. 2  F and G) . These results clearly indicate that K3-SPG is a more prominent adjuvant than K3 alone.
SPG Is a Soluble Dectin-1 Ligand but Is Not a Dectin-1 Agonist. We examined the role of Dectin-1 in cellular uptake of, and following activation by, SPG and K3-SPG, as Dectin-1 has been shown to be a receptor for β-glucans such as Zymosan (27) . Using flow cytometry, we found that HEK293 cells expressing Dectin-1 but not Dectin-2 or a control (vector) increased the uptake of SPG or K3-SPG in vitro regardless of ODN presence ( Fig. 3 A  and B) . It has recently been reported that the soluble form of β-glucan does not activate Dectin-1 signaling (28). Additionally, Dectin-1 signaling inhibits TLR9-mediated cytokine production through suppressor of cytokine signaling 1 induction (29) . Therefore, we examined the agonistic activity of SPG. When splenocytes were stimulated with Zymosan-Depleted but not SPG, dose-and Dectin-1-dependent TNF-α and other cytokine production was observed, whereas cytokine production by Zymosan and Curdlan was Dectin-1-independent ( Fig. 3C and Fig. S4 ). Zymosan-Depleted inhibited CpG ODN-induced IFN-α, with this inhibition relieved by Dectin-1 deficiency (Fig. 3D) . In contrast, SPG did not inhibit CpG ODN-induced IFN-α production (Fig. 3E) . These results indicate that SPG is a ligand but not an agonist of Dectin-1; therefore, SPG does not interfere with TLR9-mediated IFN-α production.
Adjuvant Effects of K3-SPG Are Dependent on TLR9 and Partially Dependent on Dectin-1. Because K3-SPG is a complex of CpG ODN and β-glucan, we examined the role of TLR9 (1) and Dectin-1 (30) using receptor knockout mice. When splenocytes and Flt3 ligand-induced bone marrow-derived DCs (FL-DCs) from Tlr9-and Dectin-1-deficient mice were stimulated with K3-SPG, cytokine production was completely dependent on TLR9 but not Dectin-1, excluding IL-12 p40 production (Fig. 4 A-D) . K3-SPG-induced IL-12 p40 production showed two peaks, where the first peak of its production, but not the second peak at a higher dose, was dependent on Dectin-1 (Fig. 4D) . This result may imply that Dectin-1 expression is involved in IL-12 p40 production at a lower dose of K3-SPG in vitro. Consistent with in vitro results, immunization of Tlr9-deficient mice with K3-SPG plus OVA resulted in diminished humoral and T-cell responses (Fig. 4  E-G) . Dectin-1-deficient mice showed comparable immune responses with wild-type mice when the mice were immunized with OVA plus 10 μg of K3-SPG (Fig. S5) . When Dectin-1-deficient mice were immunized with OVA plus 1 μg of K3-SPG, mice exhibited a reduced CD8 T-cell response according to the tetramer assays (Fig. 4J) , with no significant changes in antibody and cytokine production from T cells (Fig. 4 H and I) . These results suggest that the adjuvant effect of K3-SPG is dependent on TLR9 signaling. Although SPG and K3-SPG do not stimulate Dectin-1 signaling, the effect of K3-SPG is still partially dependent on Dectin-1 in vivo. Given that K3-SPG provides potent adjuvant effects in vivo through immunization with a simple antigen mixture, we hypothesized that cells that capture both antigen and K3-SPG should play a critical role in mediating adjuvant effects. To examine in vivo distribution of fluorescence-labeled OVA and K3-SPG, we used fluorescence microscopy and two-photon microscopy. After an injection at the Zymosan, Curdlan, Zymosan-Depleted (ZD), or SPG (3.7-100 μg/mL) (C), with D35 (1 μM), or with or without ZD (11.1-100 μg/mL) (D) or SPG (E) for 24 h and supernatant cytokines were monitored by ELISA. *P < 0.05 (t test). Data represent one of three independent experiments with similar results.
base of the tail, both antigen and adjuvant reached the surface of draining inguinal lymph nodes (iLNs) within 1 h (Fig. 5 A, B , and D). After 24 h, some K3-SPG had moved to the CD3e + T-cell area and colocalized with DQ-OVA (Fig. S6A ). Those cells that contained both K3-SPG and DQ-OVA in the T-cell area of the iLNs were CD11c + DCs (Fig. S6B ). Of interest, the majority of fluorescence signals remained on the surface of the iLNs (Fig. 5A) , prompting us to focus on two types of macrophages known to be distributed on the LN surface, Siglec-1 + (also called CD169 or MOMA-1) macrophages (also known as subcapsular sinus macrophages) and MARCO + macrophages (31) . Histological analysis using conventional fluorescence microscopy did not suitably reveal the entire iLN surface; moreover, these macrophages were difficult to isolate for flow cytometric analysis (32, 33) . Hence, we used two-photon microscopy imaging analysis to clarify the distribution of antigen and K3-SPG ex vivo. After the injection of anti-MARCO and -Siglec-1 antibodies, specific macrophages were visualized (Movie S1). When the iLN surface was monitored by two-photon microscopy at 1 h postinjection, OVA and K3-SPG were colocalized with MARCO + but not Siglec-1 + macrophages (Fig. 5 B and D, Fig.  S7 A-D, and Movies 2-5). Previous reports suggest that the immune complex and inactivated influenza virus are captured by Siglec-1 + macrophages to induce humoral immune responses (34, 35) . The distribution pattern perfectly matched that for MARCO + macrophages in the iLNs and did not colocalize with Siglec-1 + macrophages, as confirmed by Volocity's colocalization analysis (Perkin Elmer) (Fig. 5 B-E) . In contrast, K3 was more diffusely distributed between MARCO + and Siglec-1 + areas compared with K3-SPG (Fig. 5 D and E, Fig. S7 C-E, and Movies 6 and 7). Additionally, both Tlr9-and Dectin-1-deficient mice showed comparable localization of K3-SPG (Fig. S7 F  and G) .
To determine the contribution of these macrophages toward the adjuvant effects of K3-SPG, we examined different recovery kinetics of macrophages and DCs following an injection of clodronate liposomes into the base of the tail. After the injection, the macrophages were completely depleted by day 2. These cells did not recover for at least 1 wk, whereas DCs were mostly recovered by day 7, as previously reported (36) . When both macrophages and DCs were depleted, immune responses were significantly suppressed [ Fig. 5F , Clo (−d2)]. When only macrophages, but not DCs, were depleted, the immune responses were comparable to those in untreated mice [ Fig. 5F , Clo (−d7)]. This would suggest that although both OVA and K3-SPG were mainly captured by MARCO + macrophages in the LNs after injection, the macrophages were dispensable to inducing adaptive immune responses. In other words, the adjuvant effect of K3-SPG was largely dependent on the DC population.
K3-SPG Targets and Strongly Activates the Antigen-Bearing DC Population in Vivo. Our findings suggest that although a large portion of nanoparticulate K3-SPG was taken up by MARCO + macrophages in iLNs after injection, the adjuvant effects appear to be controlled by DCs. We focused on antigen and adjuvant uptake by the DC population in iLNs. At 24 h postinjection, the uptake of antigen and adjuvants by the DC population was analyzed by flow cytometry. The frequency of CpG-positives in three DC subsets (pDCs, CD8α
+ DCs, and CD8α − DCs) was significantly increased after K3-SPG injection than with K3 (Fig. S8A) . In contrast, the frequency of OVA-positive DCs was comparable after K3 and K3-SPG injections (Fig. S8B) . When we focused on both antigen-and adjuvant-positive DCs, there was a substantial increase for K3-SPG over K3 (Fig. S9) . Both pDCs and CD8α + DCs in iLNs were strongly activated by K3-SPG but not by K3 24 h postinjection, and this was completely dependent on TLR9 (Fig. 5G) . Our results indicate that pDCs and CD8α
+ DCs preferentially capture nanoparticulate K3-SPG rather than nonparticulate K3 for maturation and to exert adjuvant effects.
K3-SPG Is a Potent Adjuvant for Influenza Vaccine in Murine and
Nonhuman Primate Models. Finally, we sought the adjuvant effect of K3-SPG by using more clinically relevant influenza vaccination models in both mice and nonhuman primates. When mice were immunized with ether-treated hemagglutinin antigenenriched virion-free split vaccine (SV) plus the indicated adjuvant, K3-SPG demonstrated superior adjuvant effects to K3 when antibody responses (Fig. S10A ) and T-cell responses (Fig.  S10B) were compared. More importantly, SV plus K3-SPG immunization resulted in a 100-fold greater antibody response, even compared with vaccination using a whole (virion) inactivated vaccine (WIV) (0.2 μg per mouse) (Fig. 6A) , which contains viral RNA as a built-in adjuvant (21) . Interestingly, SV (0.1 μg per mouse) plus K3-SPG strongly induced both CD8 and CD4 T-cell responses (Fig. 6B ). Mice immunized with SV and K3-SPG exhibited less body weight loss than WIV-immunized mice (Fig. 6C) . Strikingly, K3-SPG conferred 100% protection against lethal PR8 virus challenge at the dose of which only 10% of WIV-vaccinated mice survived (Fig. 6D) . These results strongly support the notion that K3-SPG works as a potent adjuvant for protein or protein-based vaccines in a murine model, prompting us to extend this finding to a nonhuman primate model using the cynomolgus monkey (Macaca fascicularis). Each group of three cynomolgus monkeys was immunized with SV plus K3 or K3-SPG at days 0 and 14. Serum antibody titers were then monitored for 8 wk. The SV plus K3-SPG induced significantly higher antibody titer at 2 wk postimmunization, and titer levels remained high for at least another 6 wk (Fig. 6E) . Although antibody titers were reduced at 110 wk after immunization, the K3-SPG group had higher antibody titers than the K3 group (Fig.  6E) . When PBMCs were stimulated with SV and WIV, IFN-γ was detected from the SV plus K3-SPG-immunized group (Fig.  6F) . Taken together, these results suggest that K3-SPG is a prominent vaccine adjuvant in a nonhuman primate model.
Discussion
The medical need for novel, potent, and safe adjuvants is everincreasing these days as (i) recombinant vaccine antigens such proteins and peptides are short on natural adjuvants, unlike attenuated or inactivated whole microbial antigens, (ii) conventional aluminum salts and oil adjuvants are limited or preferred for enhancing humoral immune responses, and (iii) new adjuvants that can induce cellular immune responses, including CTLs, are needed, for example for cancer vaccines. The last two decades have resulted in tremendous progress with respect to adjuvant research and development. A hallmark of the new generation of adjuvants is that nucleic acids have been rediscovered to be immunologically active in stimulating specific innate immune receptors of the host, in particular TLRs. CpG DNA, a ligand for TLR9, is one of the most promising immunotherapeutic agents that has been identified.
Although there are several types of potent humanized CpG ODN-K (also called B), D (A), C, and P types-the development of an all-in-one CpG ODN activating both B cells and pDCs to form a stable nanoparticle without aggregation has been less than successful. In this study, we generated a novel K CpG ODN that we designated K3-SPG. Although it had been reported that there are molecular interactions between single-stranded nucleic acids and β-glucan (37) and that murine and humanized CpG ODNs can be wrapped by SPG to increase their original TLR9-agonistic activities (20) , our report demonstrates that a rod-shaped nano-sized K3-SPG particle exhibits dual characteristics of K and D CpG ODNs (Fig. 1) . K3-SPG is distinct from other previously reported K CpG ODNs, including K3. In turn, K3-SPG becomes a D CpG ODN, stimulating human PBMCs to produce large amounts of both type I and type II IFN, targeting the same endosome where the IFN-inducing D type resides without losing its K-type activity (Fig. 1 F and G) . Another surprising finding is that this K3-SPG forms a rod-like single nanomolecule ( Fig. 1 C and D) . This is advantageous over previously demonstrated D or P types, whose ends form higher-order structures that may hamper further development as prodrugs, including good manufacturing practice assignment.
Another prominent feature of this K3-SPG is its potency as an adjuvant for induction of both humoral and cellular immune responses, especially CTL induction, to coadministered protein antigens without conjugation. Such potent adjuvant activity of K3-SPG is attributable to its nanoparticulate nature (Figs. 1 C and D and 2) rather than targeting Dectin-1 by SPG (Figs. 3 and  4) . Initially, we hypothesized that K3-SPG becomes such a potent adjuvant because it targets Dectin-1, because SPG is a β-1,3-glucan, and seems to be a clear Dectin-1 ligand (Fig. 3A) . Our other results, however, led us to conclude that the role of Dectin-1 in vivo with respect to the adjuvant activity of K3-SPG was minimal (Fig. 4) . More importantly, the in vivo activity of K3-SPG was completely dependent upon TLR9 (Fig. 4 E-G) . SPG is a soluble Dectin-1 ligand but not a Dectin-1 agonist, and thus does not interfere with TLR9-mediated DC activation (Fig. 3 D  and E) . The adjuvant activity of K3-SPG is mostly independent of Dectin-1, except at very low doses during the immunization protocol (Fig. 4J) . Instead, some other receptors such as C-type lectins, Siglecs, and scavenger receptors may play roles in delivering SPG into macrophages and/or DCs, accumulating and activating antigen-bearing macrophages and DCs in draining lymph nodes (Fig. 5) . In this regard, we also found that MARCO + , but not Siglec-1 + , macrophages in draining lymph nodes are dominant in capturing K3-SPG, and coadministered antigen (LPS-free OVA protein), and that K3-SPG targets the antigen-bearing DC population in vivo. Although the depletion of macrophages did not ameliorate adjuvant effects, large amounts of antigen and K3-SPG are taken up by the same MARCO + macrophages, and the twophoton microscopic data suggest that they are activated as they become much bigger than nonstimulated macrophages. Whether this massive accumulation of antigen and adjuvant in MARCO + macrophages contributes to the following DC activation and adaptive T-and B-cell activation is yet to be elucidated in future work.
The protective potency of K3-SPG as an influenza vaccine adjuvant was demonstrated in vivo in both murine and nonhuman primate models. In the murine model, intradermal immunization with a very low dose of seasonal influenza split vaccine mixed with K3-SPG in solution provoked robust IgG responses and offered better protection than a low but physiological dose of whole inactivated virion vaccination against the heterologous challenge of lethal virus (Fig. 6 C and D) . These data provide better protective potency than our previous results, where we used approximately 10 times higher doses of influenza antigens (21) , because many factors for K3-SPG have been improved for its potency: K3-SPG complexation efficiency and optimization of the order between K3 and poly(dA 40 ) (Fig. 1) ; the immunization route is different as well. The data above prompted us to develop K3-SPG as a potent adjuvant for influenza split vaccine, especially for those urgently needing improvement: seasonal influenza vaccination for the elderly, immunodeficient patients (transplant recipients), and pandemic influenza vaccination.
Taken together, these data suggest that K3-SPG can be used as a potent adjuvant for protein vaccines such as influenza split vaccines, and may be useful for immunotherapeutic applications that require type I and type II IFN as well as CTL induction.
Materials and Methods
All animal studies using mice and monkeys were conducted in accordance with the Institutional Animal Care and Use Committee at the National Institute of Biomedical Innovation. All of the ODNs used in this manuscript were synthesized by GeneDesign. Other details are described in SI Materials and Methods.
